Medial EarlySign

With encouraging news of the vaccines against COVID-19 and the upcoming global roll-out on the horizon, we must not grow complacent in following CDC regulations. Now is the time where AI-powered clinical solutions can prove highly impactful by utilizing predictive measures to assist in minimizing the impact of coronavirus. Through reducing the care management burden by more accurately stratifying those at the highest risk for complications, we can create deeper and more personalized understanding of disease progress across both infectious and chronic complications. EarlySign’s AI-powered Infectious and chronic bundles help healthcare providers identify and prioritize patients that would benefit most from both in-person and digital early interventions. Learn more about how AI is changing the future of medicine. https://zd.net/3m1yhhH http://bit.ly/3avG6sF

From open source to AI, tech is changing everything about the future of medicine | ZDNet The coronavirus pandemic has caused significant shifts in how healthcare is delivered. How many of these advances will last beyond the virus?

2020 was a year like no other. We have witnessed devastating loss and changes on a global scale, yet in parallel, we have seen demonstrations of great courage, sacrifice, and ingenuity in battling this pandemic. We are grateful that 2020 has also brought out the best in us, rising to meet many challenges and doing so with grace and dignity. From Medial Early Sign, we wish you and your loved ones a Healthy Holiday season and a Happy New Year!

Being chosen as a finalist to participate in stage 2 of the Centers for Medicare and Medicaid Services AI Challenge is an accomplishment we are humbled to receive. Partnering together, Geisinger and Medial EarlySign are working towards reshaping the integration of clinical care with AI-driven insights by utilizing the shared knowledge of our dynamic teams. As part of a national effort guided by CMS, we are striving to find a solution to achieve the Quadruple Aim of improving the patient experience of care, improving the health of populations, reducing cost, and improving clinical care provider satisfaction.

CEO Ori Geva shares his thoughts on the potential impacts that Medial EarlySign, alongside our partner Geisinger, can have by participating as a finalist in stage 2 of the CMS AI Challenge. To read more:

Ori Geva on LinkedIn: The AI-based solution submitted by the joint team, comprised of Geisinger The AI-based solution submitted by the joint team, comprised of Geisinger and Medial EarlySign, has been chosen as a finalist to participate in stage 2...

Together, Medial EarlySign and Geisinger have devoted considerable resources to build an accurate set of AI based models—designed to support clinical workflow and provide transparency along with clinical value. Earning finalist status in the CMS AI challenge recognizes the hard work and dedication of our joint team to pursue the larger goal of improving health and outcomes. With our wealth of data science and clinical product development knowledge, we look forward to what the future of this project will bring for our team!